Biogen Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $257.89
- Today's High:
- $260.57
- Open Price:
- $258.92
- 52W Low:
- $188.535
- 52W High:
- $319.74
- Prev. Close:
- $258.92
- Volume:
- 568425
Company Statistics
- Market Cap.:
- $43.73 billion
- Book Value:
- 95.28
- Revenue TTM:
- $10.10 billion
- Operating Margin TTM:
- 28.6%
- Gross Profit TTM:
- $7.90 billion
- Profit Margin:
- 30.99%
- Return on Assets TTM:
- 7.49%
- Return on Equity TTM:
- 25.04%
Company Profile
Biogen Inc had its IPO on 1991-09-16 under the ticker symbol BIIB.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Biogen Inc has a staff strength of 8,725 employees.
Stock update
Shares of Biogen Inc opened at $258.92 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $257.89 - $260.57, and closed at $258.44.
This is a -0.19% slip from the previous day's closing price.
A total volume of 568,425 shares were traded at the close of the day’s session.
In the last one week, shares of Biogen Inc have slipped by -3.27%.
Biogen Inc's Key Ratios
Biogen Inc has a market cap of $43.73 billion, indicating a price to book ratio of 3.2581 and a price to sales ratio of 3.9385.
In the last 12-months Biogen Inc’s revenue was $10.10 billion with a gross profit of $7.90 billion and an EBITDA of $3.38 billion. The EBITDA ratio measures Biogen Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Biogen Inc’s operating margin was 28.6% while its return on assets stood at 7.49% with a return of equity of 25.04%.
In Q1, Biogen Inc’s quarterly earnings growth was a positive 29.6% while revenue growth was a negative 2.7%.
Biogen Inc’s PE and PEG Ratio
- Forward PE
- 18.4502
- Trailing PE
- 13.8847
- PEG
- 36.1919
Its diluted EPS in the last 12-months stands at $21.76 per share while it has a forward price to earnings multiple of 18.4502 and a PEG multiple of 36.1919. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Biogen Inc’s profitability.
Biogen Inc stock is trading at a EV to sales ratio of 4.1827 and a EV to EBITDA ratio of 10.3591. Its price to sales ratio in the trailing 12-months stood at 3.9385.
Biogen Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $24.60 billion
- Total Liabilities
- $3.01 billion
- Operating Cash Flow
- $-953000000.00
- Capital Expenditure
- $71.60 million
- Dividend Payout Ratio
- 0%
Biogen Inc ended 2024 with $24.60 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $24.60 billion while shareholder equity stood at $13.79 billion.
Biogen Inc ended 2024 with $251.30 million in deferred long-term liabilities, $3.01 billion in other current liabilities, 100000.00 in common stock, $16.85 billion in retained earnings and $5.75 billion in goodwill. Its cash balance stood at $2.90 billion and cash and short-term investments were $5.04 billion. The company’s total short-term debt was $0 while long-term debt stood at $6.28 billion.
Biogen Inc’s total current assets stands at $9.76 billion while long-term investments were $978.20 million and short-term investments were $2.14 billion. Its net receivables were $2.03 billion compared to accounts payable of $491.20 million and inventory worth $1.28 billion.
In 2024, Biogen Inc's operating cash flow was $-953000000.00 while its capital expenditure stood at $71.60 million.
Comparatively, Biogen Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $258.44
- 52-Week High
- $319.74
- 52-Week Low
- $188.535
- Analyst Target Price
- $332.26
Biogen Inc stock is currently trading at $258.44 per share. It touched a 52-week high of $319.74 and a 52-week low of $319.74. Analysts tracking the stock have a 12-month average target price of $332.26.
Its 50-day moving average was $270.22 and 200-day moving average was $283.21 The short ratio stood at 2.62 indicating a short percent outstanding of 0%.
Around 68.7% of the company’s stock are held by insiders while 8989.8% are held by institutions.
Frequently Asked Questions About Biogen Inc
Similar Industry Stocks (Drug Manufacturers-General)
Most Active
Top Gainers
Top Losers
About
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin’s lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin’s lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer’s disease and dementia, neuromuscular disorders, Parkinson’s disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.